251 related articles for article (PubMed ID: 34761625)
1. Relationship between survival outcomes and microsatellite instability, tumor infiltrating lymphocytes and programmed cell death ligand-1 expression in patients with bladder cancer and radical cystectomy.
Tural D; Akar E; Baytekin HF; Canoglu D; Yilmaz M; Tugcu V
J BUON; 2021; 26(5):2117-2125. PubMed ID: 34761625
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy.
Murakami Y; Matsumoto K; Shimizu Y; Ikeda M; Amano N; Shimura S; Ishii D; Sato Y; Iwamura M
Urol Oncol; 2021 Mar; 39(3):195.e15-195.e23. PubMed ID: 33071109
[TBL] [Abstract][Full Text] [Related]
3. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.
Morihiro T; Kuroda S; Kanaya N; Kakiuchi Y; Kubota T; Aoyama K; Tanaka T; Kikuchi S; Nagasaka T; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
Sci Rep; 2019 Mar; 9(1):4633. PubMed ID: 30874607
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA.
Jeon HM; Lee JS; Kim SH; Yun KH; Park KH; Jeon MK; Lee YH; Yoon HI; Suh JS; Hur H; Kim KS; Kim S; Kim SH; Kim HS
Oncology; 2020; 98(11):817-826. PubMed ID: 32892196
[TBL] [Abstract][Full Text] [Related]
6. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
[TBL] [Abstract][Full Text] [Related]
7. The expression of SP263 in muscle invasive bladder carcinoma and its relationship with clinicopathological features.
Bai Y; Wu X; Weng M; Han Q; Xu L; Chang C; Teng X
Indian J Pathol Microbiol; 2023; 66(4):702-707. PubMed ID: 38084519
[TBL] [Abstract][Full Text] [Related]
8. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer.
Horimoto Y; Thinzar Hlaing M; Saeki H; Kitano S; Nakai K; Sasaki R; Kurisaki-Arakawa A; Arakawa A; Otsuji N; Matsuoka S; Tokuda E; Arai M; Saito M
Cancer Sci; 2020 Jul; 111(7):2647-2654. PubMed ID: 32449246
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the Ki67 index and programmed death-ligand 1 expression after radical cystectomy in patients with muscle-invasive bladder cancer.
Horiguchi H; Hatakeyama S; Yoneyama T; Yoneyama MS; Tanaka T; Fujita N; Okamoto T; Yamamoto H; Yoneyama T; Yoshizawa T; Hashimoto Y; Kawaguchi T; Ohyama C
Urol Oncol; 2021 Apr; 39(4):238.e9-238.e17. PubMed ID: 33308976
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability.
Giuffrida P; Arpa G; Grillo F; Klersy C; Sampietro G; Ardizzone S; Fociani P; Fiocca R; Latella G; Sessa F; D'Errico A; Malvi D; Mescoli C; Rugge M; Nesi G; Ferrero S; Furlan D; Poggioli G; Rizzello F; Macciomei MC; Santini D; Volta U; De Giorgio R; Caio G; Calabrò A; Ciacci C; D'Armiento M; Rizzo A; Solina G; Martino M; Tonelli F; Villanacci V; Cannizzaro R; Canzonieri V; Florena AM; Biancone L; Monteleone G; Caronna R; Ciardi A; Elli L; Caprioli F; Vecchi M; D'Incà R; Zingone F; D'Odorico A; Lenti MV; Oreggia B; Reggiani Bonetti L; Astegiano M; Biletta E; Cantoro L; Giannone AG; Orlandi A; Papi C; Perfetti V; Quaquarini E; Sandri G; Silano M; Usai P; Barresi V; Ciccocioppo R; Luinetti O; Pedrazzoli P; Pietrabissa A; Viglio A; Paulli M; Corazza GR; Solcia E; Vanoli A; Di Sabatino A
Mod Pathol; 2020 Jul; 33(7):1398-1409. PubMed ID: 32066859
[TBL] [Abstract][Full Text] [Related]
14. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
[TBL] [Abstract][Full Text] [Related]
15. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
16. The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History.
Mignon S; Willard-Gallo K; Van den Eynden G; Salgado R; Decoster L; Marien KM; Vansteenkiste JF; Teugels E; De Grève J
Pathol Oncol Res; 2020 Apr; 26(2):1221-1228. PubMed ID: 31228073
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
[TBL] [Abstract][Full Text] [Related]
18. [Expression level and prognostic value of PD-L1 in microsatellite instability-high gastric cancer].
Wang XY; Hu YJ; Dong K; Zhao C; Huang XZ; Lian SY; Sun Y
Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1114-1119. PubMed ID: 33152814
[No Abstract] [Full Text] [Related]
19. Prognostic Value of Programmed Cell Death-Ligand 1 Expression in Tumor-Infiltrating Lymphocytes and Viral Load in Peripheral Blood Mononuclear Cells for Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma.
Hu B; Sun M; Wang Z; Zheng Y; Cai W; Shi HH; Zhuang Y; Lin Q
Clin Chem; 2020 Sep; 66(9):1219-1227. PubMed ID: 32870999
[TBL] [Abstract][Full Text] [Related]
20. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
